FBLG · XBRL financial data
FibroBiologics financial statements, every fiscal year
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (FBLG's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Research and development | 2,368 | 4,504 | 7,407 |
| General and administrative | 6,521 | 9,233 | 9,242 |
| Total operating expenses | 8,889 | 13,737 | 16,649 |
| Operating income (loss) | (8,889) | (13,737) | (16,649) |
| Interest income | — | 251 | 247 |
| Interest expense | 147 | 20 | 204 |
| Other income (expense) | (213) | 32 | (619) |
| Income tax expense (benefit) | 0 | 0 | 0 |
| Net income (loss) | (16,485) | (11,161) | (18,646) |
| Earnings per share, basic‡ USD per share | (13.60) | (6.80) | (8.40) |
| Earnings per share, diluted‡ USD per share | (13.60) | (6.80) | (8.40) |
| Weighted average shares, basic‡ thousands of shares | 1,412 | 1,644 | 2,233 |
| Weighted average shares, diluted‡ thousands of shares | 1,412 | 1,644 | 2,233 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2026); filings made before it reported them unadjusted.
Balance sheet
CSVFiscal years (FBLG's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Cash and cash equivalents | 9,163 | 13,985 | 4,894 |
| Total current assets | 9,215 | 14,228 | 6,349 |
| Property and equipment, net | 797 | 824 | 842 |
| Right-of-use asset | 1,809 | 1,393 | 2,380 |
| Total assets | 11,821 | 16,445 | 9,619 |
| Total current liabilities | 9,183 | 12,726 | 1,759 |
| Lease liability, non-current | 1,385 | 984 | 1,704 |
| Total liabilities | 10,568 | 13,710 | 3,463 |
| Accumulated deficit | (24,357) | (35,518) | (54,164) |
| Total stockholders' equity | 1,253 | 2,735 | 6,156 |
| Total liabilities and equity | 11,821 | 16,445 | 9,619 |
| Common shares outstanding (cover page)‡ thousands of shares | 1,632 | 1,887 | 3,380 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2026); filings made before it reported them unadjusted.
Cash flows
CSVFiscal years (FBLG's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Net income (loss) | (16,485) | (11,161) | (18,646) |
| Stock-based compensation | 1,765 | 2,219 | 2,686 |
| Net cash from operating activities | (6,401) | (11,901) | (16,394) |
| Purchases of property and equipment | 495 | 184 | 262 |
| Net cash from investing activities | (495) | (184) | (262) |
| Proceeds from issuing common stock | — | 7,507 | 6,590 |
| Proceeds from issuing equity | 16,418 | — | — |
| Net cash from financing activities | 13,793 | 16,907 | 7,565 |
| Net change in cash | 6,897 | 4,822 | (9,091) |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| FibroBiologics | 3,515 | not reported | (3,291)* | 6.7M | 1.1 quarters | 10-QJun 30, 2026 |
| Dare Bioscience | 12,618 | 188 | (6,775)* | 15.3M | 1.9 quarters | 10-QJun 30, 2026 |
| Lunai Bioworks | 1,714 | 31* | (1,841)* | 5.0M | 0.9 quarters | 10-KJun 30, 2026 |
| Imunon | 6,864 | not reported | (3,025)* | 5.6M | 2.3 quarters | 10-QJun 30, 2026 |
| Aptose Biosciences | 1,020 | not reported | (5,841) | 2.6M | 0.2 quarters | 10-QMar 31, 2026 |
| Armata Pharmaceuticals | 23,952 | not reported | (8,666)* | 37.2M | 2.8 quarters | 10-QJun 30, 2026 |
| Ovid Therapeutics | 11,327 | 733 | (17,594)* | 195.3M | 6.7 quarters | 10-QJun 30, 2026 |
| Fibrogen | 50,644 | (1,474) | (3,991)* | 4.0M | 22.9 quarters | 10-QJun 30, 2026 |
| vTv Therapeutics | 86,643 | 0 | (11,443)* | not reported | 7.6 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.